TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (“TransCode or the “Company”) announces that it entered into a definitive agreement to acquire Polynoma LLC, a privately-held biotechnology immuno-oncology company. Polynoma is developing a late-stage candidate, seviprotimut-L, a novel polyvalent shed antigen vaccine for the adjuvant treatment of stage IIB and IIC melanoma. Concurrent with the Polynoma acquisition, TransCode announced a $25 million investment from CK Life Sciences Int’l., (Holdings) Inc. (“CK Life Sciences”) to be used primarily to advance clinical development of TransCode’s lead microRNA asset, TTX-MC138, into a Phase 2 clinical trial.
Read the full article: TransCode Therapeutics Announces the Acquisition of Polynoma //
Source: https://www.prnewswire.com/news-releases/transcode-therapeutics-rnaz-announces-the-acquisition-of-polynoma-and-a-25-million-strategic-financing-by-a-subsidiary-of-ck-life-sciences-to-form-a-first-in-class-unique-immuno-oncology-and-metastatic-prevention-oncology-compa-302578286.html